Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients

The objective of this study was to evaluate the triazole anti-fungal agent, voriconazole, as therapy for systemic Penicillium marneffei infections in patients with advanced HIV infection. Patients with systemic P. marneffei infection were enrolled into a study of voriconazole for the treatment of le...

Full description

Saved in:
Bibliographic Details
Main Authors: Khuanchai Supparatpinyo, Haran T. Schlamm
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34848818796&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61129
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-61129
record_format dspace
spelling th-cmuir.6653943832-611292018-09-10T04:07:56Z Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients Khuanchai Supparatpinyo Haran T. Schlamm Immunology and Microbiology Medicine The objective of this study was to evaluate the triazole anti-fungal agent, voriconazole, as therapy for systemic Penicillium marneffei infections in patients with advanced HIV infection. Patients with systemic P. marneffei infection were enrolled into a study of voriconazole for the treatment of less common, emerging, or refractory fungal infections. Patients were eligible for inclusion in the study on the basis that no anti-fungal agents have received regulatory approval specifically for P. marneffei infections. Patients were treated in the hospital setting with intravenous voriconazole (6 mg/kg every 12 hours on Day 1 and then 4 mg/kg every 12 hours for at least 3 days, after which patients could switch to oral therapy at 200 mg twice a day) or as outpatients with oral voriconazole (400 mg twice a day on Day 1 and then 200 mg twice a day) for a maximum of 12 weeks. Eleven patients received treatment with voriconazole. Two received short courses of intravenous therapy followed by the oral formulation; nine were treated with oral voriconazole only. At the end of therapy, eight of the nine evaluable patients had favorable response to therapy, based on mycological and clinical findings. There were no relapses of P. marneffei infection in the six patients who were seen at follow-up within 4 weeks of the end of therapy. Treatment with voriconazole was well tolerated, with no discontinuations caused by drug-related adverse events. The results of this study suggest that voriconazole is an effective, well-tolerated, and convenient option for the treatment of systemic infections with P. marneffei. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene. 2018-09-10T04:05:07Z 2018-09-10T04:05:07Z 2007-08-01 Journal 00029637 2-s2.0-34848818796 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34848818796&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61129
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Immunology and Microbiology
Medicine
spellingShingle Immunology and Microbiology
Medicine
Khuanchai Supparatpinyo
Haran T. Schlamm
Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients
description The objective of this study was to evaluate the triazole anti-fungal agent, voriconazole, as therapy for systemic Penicillium marneffei infections in patients with advanced HIV infection. Patients with systemic P. marneffei infection were enrolled into a study of voriconazole for the treatment of less common, emerging, or refractory fungal infections. Patients were eligible for inclusion in the study on the basis that no anti-fungal agents have received regulatory approval specifically for P. marneffei infections. Patients were treated in the hospital setting with intravenous voriconazole (6 mg/kg every 12 hours on Day 1 and then 4 mg/kg every 12 hours for at least 3 days, after which patients could switch to oral therapy at 200 mg twice a day) or as outpatients with oral voriconazole (400 mg twice a day on Day 1 and then 200 mg twice a day) for a maximum of 12 weeks. Eleven patients received treatment with voriconazole. Two received short courses of intravenous therapy followed by the oral formulation; nine were treated with oral voriconazole only. At the end of therapy, eight of the nine evaluable patients had favorable response to therapy, based on mycological and clinical findings. There were no relapses of P. marneffei infection in the six patients who were seen at follow-up within 4 weeks of the end of therapy. Treatment with voriconazole was well tolerated, with no discontinuations caused by drug-related adverse events. The results of this study suggest that voriconazole is an effective, well-tolerated, and convenient option for the treatment of systemic infections with P. marneffei. Copyright © 2007 by The American Society of Tropical Medicine and Hygiene.
format Journal
author Khuanchai Supparatpinyo
Haran T. Schlamm
author_facet Khuanchai Supparatpinyo
Haran T. Schlamm
author_sort Khuanchai Supparatpinyo
title Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients
title_short Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients
title_full Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients
title_fullStr Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients
title_full_unstemmed Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients
title_sort voriconazole as therapy for systemic penicillium marneffei infections in aids patients
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34848818796&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61129
_version_ 1681425563322941440